Paraoxonase-1 and Simvastatin Treatment in Patients with Stable Coronary Artery Disease

Table 3

The effect of Q192R and L55M polymorphisms on serum PON1 activity.

	CAD group	Controls		PON1 activity (U/L)
	(%)	(%)		CAD group	Controls
Number of subjects (%)	53 (100)	53 (100)	1.0	126.58 ± 85.95	125.94 ± 79.56	0.91
Q192R polymorphism
Genotype
QQ	32 (60.4)	31 (58.5)	0.84	66.04 ± 9.64	72.28 ± 14.19	0.14
QR	17 (32.1)	18 (34)	0.83	196.54 ± 48.24	182.76 ± 40.5	0.43
RR	4 (7.5)	4 (7.5)	1.0	302.75 ± 91.65	313.75 ± 72.28	0.85
192R allele carriers	21 (39.6)	22 (41.5)	0.84	215.05 ± 70.35	207.71 ± 67.23	0.65
L55M polymorphism
Genotype
LL	14 (24.6)	18 (34)	0.39	126.13 ± 77.26	136.06 ± 83.35	0.44
LM	31 (58.5)	18 (34)	0.01	113.85 ± 68.6	112.8 ± 69.43	0.54
MM	8 (15.1)	17 (32)	0.039	163.90 ± 134.64	122.82 ± 95.62	0.74

Data is presented as arithmetic means ± SD; Chi² test; Mann-Whitney test.